The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3 year $3.75m (£3.12m) bacteria prod'n agreement

18 Mar 2020 07:00

RNS Number : 5261G
Integumen PLC
18 March 2020
 

AIM share code: SKIN

18 March 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen signs three year $3.75m (£3.12m) bacteria production agreement with Modern Water plc

 

Labskin Laboratories to expand 100% in Q2 2020 to meet increased demand

 

Integumen announces that it has signed a three-year revenue-sharing, manufacturing agency agreement ("Agreement") with Modern Water plc ("Modern Water") to manufacture and provide logistic support for the Modern Water's monitoring reagent consumables. The Agreement is for $1.25m (£1.04m) per year for 3-years, worth a total of $3.75m (£3.12m). The revenue share split is 60% / 40% in favour of Modern Water, after costs, and is subject to rolling 12-month extensions thereafter.

 

In addition, Integumen confirms a further 100% expansion of its purpose-built product and development laboratories in York, UK, to 6,000 square feet, adding six more laboratory rooms to meet growing demand. Two of those laboratories will be allocated to the production of Modern Water's bacteria reagent. As part of the Agreement, a further three full-time laboratory technicians will be recruited to join Integumen's team of highly skilled scientific specialists in bacteria, virus and toxins.

 

Gerard Brandon CEO Integumen plc commented:

"We are delighted to announce the continued expansion of our laboratories and to be able to provide European bacteria reagent manufacturing capacity and logistic support to Modern Water's sales, marketing and distribution in the US, EU, China and Japan. This Agreement demonstrates demand for Integumen's services and our capacity to maintain exponential growth regardless of the uncertainties of Brexit or the Coronavirus. In addition to production of the bacteria reagents, our AI division is exploring options to develop data analytic tools for Modern Water monitoring equipment, with the potential to add higher-value bolt-on real-time alert services leading to increased revenue per client."

 

Simon Humphrey CEO of Modern Water, commented:

"This Agreement is a water-shed moment for Modern Water. We are moving from a self-contained production, sales, marketing and distribution company to a collaborative, cooperation and partnership business model. This immediately gives Modern Water access to state-of-the art laboratories in the UK without the need for capital expenditure. Integumen's superior development and manufacturing capabilities will enable us to rapidly grow our existing network of sales, marketing and distribution channels, delivering the quality of product we are synonymous with, whilst lowering operational costs."

 

Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

Notes:

Gerard Brandon is CEO, Executive Director and a shareholder of Integumen and is also Non-Executive Chairman and shareholder of Modern Water. Given this conflict of interest, Gerard is not regarded as independent and has taken no part in the Company's consideration or the decision to enter into the Agreement with Modern Water. Ross Andrews, Non-Executive Chairman, Fin Murray, Executive Director, and Camillus Glover, Executive Director, are regarded as independent and have evaluated and agreed the final terms of the Agreement.

 

About Integumen plc

Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

About Modern Water

Modern Water was established in 2006 to develop and commercialise water recovery technologies to counter water crisis problems arising from climate change and a growing global population. Having invested £20m over the last 14 years, the results comprise of a robust patent portfolio in cutting-edge technology, focussed on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRUBVNRRVUOAAR
Date   Source Headline
7th Sep 20202:08 pmRNSForm 8.3 - Integumen plc
7th Sep 202012:30 pmRNSRule 2.9 Announcement - update
4th Sep 20205:31 pmRNSForm 8.3 - Integumen plc
4th Sep 20205:31 pmRNSForm 8.3 - Integumen plc
4th Sep 20203:36 pmRNSForm 8.3 - Integumen PLC
3rd Sep 20203:56 pmRNSForm 8.3 - Integumen plc
3rd Sep 202011:05 amRNSSecond Price Monitoring Extn
3rd Sep 202011:02 amGNWForm 8.3 - Integumen Plc
3rd Sep 202011:00 amRNSPrice Monitoring Extension
2nd Sep 202010:50 amRNSForm 8.3 - Integumen plc
2nd Sep 20207:18 amRNSForm 8.3 - Integumen plc
1st Sep 20205:35 pmRNSNotice of AGM
1st Sep 20204:40 pmRNSSecond Price Monitoring Extn
1st Sep 20204:35 pmRNSPrice Monitoring Extension
1st Sep 202012:05 pmGNWForm 8.3 - Integumen Plc
28th Aug 20204:49 pmRNSRule 2.9 Announcement
28th Aug 20202:45 pmRNSExercise of Warrants; Total Voting Rights
28th Aug 202011:05 amRNSSecond Price Monitoring Extn
28th Aug 202011:00 amRNSPrice Monitoring Extension
28th Aug 20208:06 amRNSRECOMMENDED ALL-EQUITY OFFER FOR MODERN WATER PLC
26th Aug 20204:41 pmRNSSecond Price Monitoring Extn
26th Aug 20204:35 pmRNSPrice Monitoring Extension
26th Aug 20201:30 pmRNSExercise of Warrants; Total Voting Rights
24th Aug 20202:37 pmRNSExercise of Warrants
21st Aug 20202:06 pmRNSSecond Price Monitoring Extn
21st Aug 20202:00 pmRNSPrice Monitoring Extension
14th Aug 20207:00 amRNSExercise of Warrants; Total Voting Rights
7th Aug 20205:17 pmRNSExercise of Warrants; Total Voting Rights
29th Jul 20207:00 amRNSIntegumen secures £3 million funding facility
24th Jul 20207:00 amRNSLabskin launches remote clinical skin trials
13th Jul 20207:00 amRNSPartners with Avacta for novel SARS-CoV-2 sensors
22nd Jun 20202:06 pmRNSSecond Price Monitoring Extn
22nd Jun 20202:00 pmRNSPrice Monitoring Extension
22nd Jun 20207:00 amRNSIntegumen COVID-19 MTA signed with Aptamer Group
15th Jun 20207:01 amRNSUnsecured Loan Facility Agreement with Cellulac
15th Jun 20207:00 amRNSFinal Results
5th Jun 20207:00 amRNSExercise of Warrants; Total Voting Rights
3rd Jun 20207:00 amRNSLabskin anti-viral COVID19 skin and dental tests
1st Jun 202011:06 amRNSSecond Price Monitoring Extn
1st Jun 202011:00 amRNSPrice Monitoring Extension
29th May 202010:49 amRNSReplacement:Exercise of Warrants;TVR
28th May 20203:30 pmRNSExercise of Warrants; Total voting rights
27th May 20202:06 pmRNSSecond Price Monitoring Extn
27th May 20202:00 pmRNSPrice Monitoring Extension
11th May 20202:05 pmRNSSecond Price Monitoring Extn
11th May 20202:00 pmRNSPrice Monitoring Extension
6th May 20204:41 pmRNSSecond Price Monitoring Extn
6th May 20204:36 pmRNSPrice Monitoring Extension
6th May 20207:00 amRNSDoubling of production of Modern Water reagent
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.